U.S., March 19 -- ClinicalTrials.gov registry received information related to the study (NCT07479485) titled 'MRG006A Combination Therapy for Advanced Hepatocellular Carcinoma (Phase I/II)' on March 09.
Brief Summary: This is an open-label, multicenter, Phase I/II clinical study designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of MRG006A in combination with immune checkpoint inhibitors and targeted therapy in patients with advanced hepatocellular carcinoma (HCC).
Study Start Date: April, 2026
Study Type: INTERVENTIONAL
Condition:
Hepatocellular Carcinoma
Intervention:
DRUG: MRG006A
Administrated intravenously
DRUG: MRG006A
Administrated intravenously
DRUG: MRG006A
Administrated intravenou...